FIELD: immunology.
SUBSTANCE: disclosed is a method for producing a double specificity antibody or antigen-binding fragment thereof, as well as antibodies and antigen-binding fragments, prepared in such a way and capable of binding interleukin-4 (IL4) and interleukin-5 (IL5) or IL4 and interleukin-13 (IL13). Antibodies with double specificity are created by identifying a monospecific antibody having residues of the variable light chain variable segment VL, which are electrostatic or hydrophobic, and changing the nucleic acid sequence coding one or more residues available in the VH of the antibody to the solvent. Also presented are pharmaceutical compositions containing such antibodies or antigen-binding fragments, and methods of treating asthma using them. Invention also discloses a polynucleotide, an expression vector, a host cell and a method of producing said antibodies or antigen-binding fragments based thereon.
EFFECT: this group of inventions can be used in production of medicinal agents.
45 cl, 8 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO S. AUREUS SURFACE DETERMINANTS | 2013 |
|
RU2698131C2 |
| ANTIBODIES TO SURFACE DETERMINANTS OF S. AUREUS | 2013 |
|
RU2808018C2 |
| ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE | 2016 |
|
RU2815681C1 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| ANTIBODIES SPECIFIC TO MMP9 | 2015 |
|
RU2714043C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
| PD-L1 ANTIBODIES BINDING DOG PD-L1 | 2015 |
|
RU2722562C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
